ERBB2 and triple-negative breast carcinoma: Complete subject data were grouped as 114 subjects with Luminal A 13% (17/114), Luminal B 45% (59/114), HER2-enriched 15% (20/114) and triple-negative breast cancer (TNBC) 14% (18/114).